Design and synthesis of novel amide AKT1 inhibitors with selectivity over CDK2

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 18, 2011, Pages 5191-5196

  Ashton, Kate S ^a   St Jean Jr , David J ^a   Poon, Steve F ^a   Lee, Matthew R ^a   Allen, John G ^a   Zhang, Shiwen ^a   Lofgren, Julie A ^a   Zhang, Xiaoling ^a   Fotsch, Christopher ^a   Hungate, Randall ^a  

^a AMGEN INC   (United States)

Author keywords

AKT; Cancer; CDK; PKB

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE 2; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; THIADIAZOLE DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; DRUG CLEARANCE; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STABILITY; DRUG SYNTHESIS; ENZYME INHIBITION; IC 50; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

AMIDES; CHEMISTRY TECHNIQUES, SYNTHETIC; CRYSTALLOGRAPHY, X-RAY; CYCLIN-DEPENDENT KINASE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; ENZYME INHIBITORS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTO-ONCOGENE PROTEINS C-AKT; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80051927351     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.07.056     Document Type: Article

References (21)

1. C.W. Lindsley, S.F. Barnett, M.E. Layton, and M.T. Bilodeau Curr. Cancer Drug Target 8 2008 7
2. Q. Li Expert Opin. Ther. Pat. 17 2007 1077
3. D.A. Heerding, I.G. Safonov, and S.K. Verma Annu. Rep. Med. Chem. 42 2007 365
4. B.T. Hennessy, D.L. Smith, P.T. Ram, Y. Lu, and G.B. Mills Nat. Rev. Drug Discovery 4 2005 988
5. A.G. Bader, S. Khang, L. Zhao, and P.K. Vogt Nat. Rev. Cancer 5 2005 921
6. J.R. Testa, and A. Bellacosa Proc. Natl. Acad. Sci. U.S.A. 98 2001 10983
7. M. Cully, H. You, A.J. Levine, and T.W. Mak Nat. Rev. Cancer 6 2006 184
8. B. Dummler, and B.A. Hemmings Biochem. Soc. Trans. 35 2007 231
9. AKT1, PKA, and CDK2 enzymatic activity was measured using a previously described method. X.L. Zhang, S.W. Zhang, H. Yamane, R. Wahl, A. Ali, J.A. Lofgren, and R.L. Kendall J. Biol. Chem. 281 2006 13949
10. U87MG cells in 5% FBS media were incubated with inhibitors in threefold serial dilutions for 1h at 37 °C. The cells were lysed and PRAS40 phosphorylation was quantified by ELISA assay. Phospho-PRAS40 was normalized to total PRAS40. K.S. Kovacina, G.Y. Park, S.S. Bae, A.W. Guzzetta, E. Schaefer, M.J. Birnbaum, and R.A. Roth J. Biol. Chem. 278 2003 10189
11. Q. Zeng, M.P. Bourbeau, G.E. Wohlhieter, G. Yao, H. Monenschein, J.T. Rider, M.R. Lee, S. Zhang, J.A. Lofgren, D.J. Freeman, C. Li, E. Tominey, X. Huang, D. Hoffman, H.K. Yamane, A.S. Tasker, C. Dominguez, V.N. Viswanadha, R. Hungate, and X. Zhang Bioorg. Med. Chem. Lett. 20 2010 1652 1656
12. Q. Zeng, J.G. Allen, M.P. Bourbeau, X. Wang, G. Yao, S. Tadesse, J.T. Rider, C.C. Yuan, F.-T. Hong, M.R. Lee, S. Zhang, J.A. Lofgren, D.J. Freeman, S. Yang, C. Li, E. Tominey, X. Huang, D. Hoffman, H.K. Yamane, C. Fotsch, C. Dominguez, R. Hungate, and X. Zhang Bioorg. Med. Chem. Lett. 20 2010 1559 1564
13. AKT1 was the only AKT isoform routinely tested against as it is thought to be the major isoform contributing to oncogenic activity. Dummler, B.; Hemmings, B. A. Biochem. Soc. Trans. 2007, 35, 231. In addition all other isoforms of AKT potency tracked well with AKT1 upon testing.
14. A. Besson, S.F. Dowdy, and J.M. Roberts Dev. Cell 14 2008 159
15. T.D. Davies, M.L. Verdonk, B. Graham, S. Saalau-Bethell, C.C.F. Hamlett, T. McHardy, I. Collins, M.D. Garrett, P. Workman, S.J. Woodhead, H. Jhoti, and D. Barford J. Mol. Biol. 367 2007 882
16. For a description of a similar crystallography strategy see: J.J. Caldwell, T.G. Davies, A. Donald, T. McHardy, M.G. Rowlands, G.W. Aherne, L.K. Hunter, K. Taylor, R. Ruddle, F.I. Raynaud, M. Verdonk, P. Workman, M.D. Garrett, and I. Collins J. Med. Chem. 51 2008 2147
17. Mutations: PKA Val123 was mutated to AKT Ala, and PKA Leu173 was mutated to AKT Met. Additionally, PKA Lys181 was mutated to AKT Gln, but this residue faces away from the ATP binding pocket. M. Gassell, C.B. Breitenlechner, P. Ruger, U. Jucknischke, T. Schnieder, R. Huber, D. Bossemeyer, and R.A. Engh J. Mol. Biol. 329 2003 1021
18. G. Saxty, S.J. Woodhead, V. Berdini, T.G. Davies, M.L. Verdonk, P.G. Wyatt, R.G. Boyle, D. Barford, R. Downham, M.D. Garrett, and R.A. Carr J. Med. Chem. 50 2007 2293 2296
19. B. Lippa, G. Pan, M. Corbett, C. Li, G.S. Kauffman, J. Pandit, S. Robinson, L. Wei, E. Kozina, E.S. Marr, G. Borzillo, E. Knauth, E.G. Barbacci-Tobin, P. Vincent, M. Troutman, D. Baker, F. Rajamohan, S. Kakar, T. Clark, and J. Morris Bioorg. Med. Chem. Lett. 18 2008 3359 3363
20. The absolute configuration of the azetidines was determined by Mosher ester analysis - see Supplementary data.
21. S. Billotte Synlett 4 1998 379 380